Top Markets
Coin of the day
IMBdx IMBdx

IMBdx

461030
Rank in Stocks #27739
IMBdx, Inc. specializes in developing advanced liquid biopsy technologies for... IMBdx, Inc. specializes in developing advanced liquid biopsy technologies for cancer detection and management. The company's core mission revolves around three key areas: facilitating the diagnosis and treatment strategies for advanced-stage cancers, enabling the early identification of cancer recurrence after surgical interventions, and providing solutions for the early diagnosis of cancer. Its notable product offerings include AlphaLiquid, CancerDetect, and CancerFind. The firm was established by Tae-Yu Kim, Sung-Tae Moon, and Doo-Hee Bang on July 5, 2018, and maintains its headquarters in Seoul, South Korea.
Share Price
$2.14
Market Cap
$30.63M
Change (1 day)
0.16%
Change (1 year)
-62.09%
Country
KR
Trade IMBdx (461030)

Category

Earnings for IMBdx (461030)
Earnings in 2026 TTM: 0
According to IMBdx latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for IMBdx from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$-3.09B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH